Novel therapies for coeliac disease

Journal of Internal Medicine

Volumn 269, Issue 6, 2011, Pages 604-613

  Sollid, L M ^a   Khosla, C ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Coeliac disease; Drug; Gluten; Human leucocyte antigen; T cell; Therapy; Transglutaminase

Indexed keywords

ALV 003; AMG 714; ASPERGILLUS NIGER PROLYL ENDOPROTEASE; AZIDOPROLINE ANALOGUE; BA 210; BUDESONIDE; CCX 282B; CINNAMOYL TRIAZOLE DERIVATIVE; FASUDIL; FONTOLIZUMAB; GLIADIN; GLUTEN; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; IBRITUMOMAB TIUXETAN; LARAZOTIDE; LEUKOCYTE ANTIGEN; METALLOPROTEINASE; OTELIXIZUMAB; POLY(HYDROXYETHYL METHACRYLATE COSTYRENE SULFONATE); PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PYRIMIDINE ANTAGONIST; RITUXIMAB; STAN 1; TEPLIZUMAB; TOSITUMOMAB; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB; ZED 101; ZONULIN;

ANTIGEN PRESENTING CELL; ASTHMA; BRAIN VASOSPASM; CELIAC DISEASE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOLOGY; DIET RESTRICTION; DISEASE ACTIVITY; DRUG DETOXIFICATION; DRUG EFFECT; DRUG EFFICACY; ENTERITIS; ENZYME INHIBITION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GLUTEN FREE DIET; HOOKWORM INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; INTERFERON PRODUCTION; INTESTINE BIOPSY; INTESTINE MUCOSA PERMEABILITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

CELIAC DISEASE; DESENSITIZATION, IMMUNOLOGIC; DRUG DISCOVERY; ENZYME INHIBITORS; GASTROINTESTINAL AGENTS; GLUTENS; GTP-BINDING PROTEINS; HUMANS; METABOLIC DETOXICATION, DRUG; MOLECULAR TARGETED THERAPY; TRANSGLUTAMINASES;

EID: 79956290534     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02376.x     Document Type: Conference Paper

References (91)

1. Green PH, Cellier C. Coeliac disease. N Engl J Med 2007; 357: 1731-43.
2. Sollid LM. Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2002; 2: 647-55.
3. Dieterich W, Ehnis T, Bauer M et al. Identification of tissue transglutaminase as the autoantigen of coeliac disease. Nat Med 1997; 3: 797-801.
4. Dieterich W, Laag E, Schopper H et al. Autoantibodies to tissue transglutaminase as predictors of coeliac disease. Gastroenterology 1998; 115: 1317-21.
5. Sulkanen S, Halttunen T, Laurila K et al. Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting coeliac disease. Gastroenterology 1998; 115: 1322-8.
6. Sollid LM, Khosla C. Future therapeutic options for coeliac disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 140-7.
7. Anderson RP. Coeliac disease: current approach and future prospects. Intern Med J 2008; 38: 790-9.
8. Lerner A. New therapeutic strategies for coeliac disease. Autoimmun Rev 2010; 9: 144-7.
9. Schuppan D, Junker Y, Barisani D. Coeliac disease: from pathogenesis to novel therapies. Gastroenterology 2009; 137: 1912-33.
10. van Heel DA, Franke L, Hunt KA et al. A genome-wide association study for coeliac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 2007; 39: 827-9.
11. Nilsen EM, Lundin KEA, Krajci P, Scott H, Sollid LM, Brandtzaeg P. Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma. Gut 1995; 37: 766-76.
12. Dubois PC, Trynka G, Franke L et al. Multiple common variants for coeliac disease influencing immune gene expression. Nat Genet 2010; 42: 295-302.
13. Trynka G, Wijmenga C, van Heel DA. A genetic perspective on coeliac disease. Trends Mol Med 2010; 16: 537-50.
14. Shan L, Molberg Ø, Parrot I et al. Structural basis for gluten intolerance in coeliac sprue. Science 2002; 297: 2275-9.
15. Molberg Ø, McAdam SN, Körner R et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells. Nat Med 1998; 4: 713-7.
16. van de Wal Y, Kooy Y, van Veelen P et al. Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J Immunol 1998; 161: 1585-8.
17. Kim CY, Quarsten H, Bergseng E, Khosla C, Sollid LM. Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in coeliac disease. Proc Natl Acad Sci USA 2004; 101: 4175-9.
18. Henderson KN, Tye-Din JA, Reid HH et al. A structural and immunological basis for the role of human leukocyte antigen DQ8 in coeliac disease. Immunity 2007; 27: 23-34.
19. Fasano A, Not T, Wang W et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet 2000; 355: 1518-9.
20. Hüe S, Mention JJ, Monteiro RC et al. A direct role for NKG2D/MICA interaction in villous atrophy during coeliac disease. Immunity 2004; 21: 367-77.
21. Meresse B, Chen Z, Ciszewski C et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in coeliac disease. Immunity 2004; 21: 357-66.
22. Jabri B, Sollid LM. Tissue-mediated control of immunopathology in coeliac disease. Nat Rev Immunol 2009; 9: 858-70.
23. Daum S, Ipczynski R, Heine B, Schulzke JD, Zeitz M, Ullrich R. Therapy with budesonide in patients with refractory sprue. Digestion 2006; 73: 60-8.
24. Brar P, Lee S, Lewis S, Egbuna I, Bhagat G, Green PH. Budesonide in the treatment of refractory coeliac disease. Am J Gastroenterol 2007; 102: 2265-9.
25. Ciacci C, Maiuri L, Russo I et al. Efficacy of budesonide therapy in the early phase of treatment of adult coeliac disease patients with malabsorption: an in vivo/in vitro pilot study. Clin Exp Pharmacol Physiol 2009; 36: 1170-6.
26. Rautiainen H, Farkkila M, Neuvonen M et al. Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis. Aliment Pharmacol Ther 2006; 24: 1545-52.
27. Hausch F, Shan L, Santiago NA, Gray GM, Khosla C. Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Physiol 2002; 283: G996-1003.
28. Piper JL, Gray GM, Khosla C. Effect of prolyl endopeptidase on digestive-resistant gliadin peptides in vivo. J Pharmacol Exp Ther 2004; 311: 213-9.
29. Marti T, Molberg O, Li Q, Gray GM, Khosla C, Sollid LM. Prolyl endopeptidase-mediated destruction of T cell epitopes in whole gluten: chemical and immunological characterization. J Pharmacol Exp Ther 2005; 312: 19-26.
30. Pyle GG, Paaso B, Anderson BE et al. Effect of pretreatment of food gluten with prolyl endopeptidase on gluten-induced malabsorption in coeliac sprue. Clin Gastroenterol Hepatol 2005; 3: 687-94.
31. Bethune MT, Strop P, Tang Y, Sollid LM, Khosla C. Heterologous expression, purification, refolding, and structural-functional characterization of EP-B2, a self-activating barley cysteine endoprotease. Chem Biol 2006; 13: 637-47.
32. Siegel M, Bethune MT, Gass J et al. Rational design of combination enzyme therapy for coeliac sprue. Chem Biol 2006; 13: 649-58.
33. Gass J, Vora H, Bethune MT, Gray GM, Khosla C. Effect of barley endoprotease EP-B2 on gluten digestion in the intact rat. J Pharmacol Exp Ther 2006; 318: 1178-86.
34. Stepniak D, Spaenij-Dekking L, Mitea C et al. Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for coeliac disease. Am J Physiol Gastrointest Liver Physiol 2006; 291: G621-9.
35. Gass J, Vora H, Hofmann AF, Gray GM, Khosla C. Enhancement of dietary protein digestion by conjugated bile acids. Gastroenterology 2007; 133: 16-23.
36. Mitea C, Havenaar R, Drijfhout JW, Edens L, Dekking L, Koning F. Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut 2008; 57: 25-32.
37. Tye-Din JA, Anderson RP, Ffrench RA et al. The effects of ALV003 pre-digestion of gluten on immune response and symptoms in coeliac disease in vivo. Clin Immunol 2010; 134: 289-95.
38. Ehren J, Moron B, Martin E, Bethune MT, Gray GM, Khosla C. A food-grade enzyme preparation with modest gluten detoxification properties. PLoS ONE 2009; 4: e6313.
39. Liang L, Pinier M, Leroux JC, Subirade M. Interaction of alpha-gliadin with poly(HEMA-co-SS): structural characterization and biological implication. Biopolymers 2009; 91: 169-78.
40. Liang L, Pinier M, Leroux JC, Subirade M. Interaction of alpha-gliadin with polyanions: design considerations for sequestrants used in supportive treatment of coeliac disease. Biopolymers 2010; 93: 418-28.
41. Pinier M, Verdu EF, Nasser-Eddine M et al. Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. Gastroenterology 2009; 136: 288-98.
42. Drago S, El AR, Di PM et al. Gliadin, zonulin and gut permeability: effects on coeliac and non-coeliac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol 2006; 41: 408-19.
43. Duerksen DR, Wilhelm-Boyles C, Veitch R, Kryszak D, Parry DM. A comparison of antibody testing, permeability testing, and zonulin levels with small-bowel biopsy in coeliac disease patients on a gluten-free diet. Dig Dis Sci 2010; 55: 1026-31.
44. Smecuol E, Sugai E, Niveloni S et al. Permeability, zonulin production, and enteropathy in dermatitis herpetiformis. Clin Gastroenterol Hepatol 2005; 3: 335-41.
45. Tripathi A, Lammers KM, Goldblum S et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci USA 2009; 106: 16799-804.
46. Wang W, Uzzau S, Goldblum SE, Fasano A. Human zonulin, a potential modulator of intestinal tight junctions. J Cell Sci 2000; 24: 4435-40.
47. Paterson BM, Lammers KM, Arrieta MC, Fasano A, Meddings JB. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther 2007; 26: 757-66.
48. Nanda N, Iismaa SE, Owens WA, Husain A, Mackay F, Graham RM. Targeted inactivation of Gh/tissue transglutaminase II. J Biol Chem 2001; 276: 20673-8.
49. De Laurenzi V, Melino G. Gene disruption of tissue transglutaminase. Mol Cell Biol 2001; 21: 148-55.
50. Marrano C, de Macedo P, Gagnon P, Lapierre D, Gravel C, Keillor JW. Synthesis and evaluation of novel dipeptide-bound 1, 2, 4-thiadiazoles as irreversible inhibitors of guinea pig liver transglutaminase. Bioorg Med Chem 2001; 9: 3231-41.
51. de Macedo P, Marrano C, Keillor JW. Synthesis of dipeptide-bound epoxides and alpha, beta-unsaturated amides as potential irreversible transglutaminase inhibitors. Bioorg Med Chem 2002; 10: 355-60.
52. Choi K, Siegel M, Piper JL et al. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol 2005; 12: 469-75.
53. Watts RE, Siegel M, Khosla C. Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles. J Med Chem 2006; 49: 7493-501.
54. Duval E, Case A, Stein RL, Cuny GD. Structure-activity relationship study of novel tissue transglutaminase inhibitors. Bioorg Med Chem Lett 2005; 15: 1885-9.
55. Pardin C, Pelletier JN, Lubell WD, Keillor JW. Cinnamoyl inhibitors of tissue transglutaminase. J Org Chem 2008; 73: 5766-75.
56. Ozaki S, Ebisui E, Hamada K et al. Potent transglutaminase inhibitors, aryl beta-aminoethyl ketones. Bioorg Med Chem Lett 2010; 20: 1141-4.
57. Klöck CJ, Jin X, Choi K et al. Acylidene oxoindoles: a new class of reversible inhibitors of human transglutaminase 2. Bioorg Med Chem Lett 2011 (in press).
58. Siegel M, Strnad P, Watts RE et al. Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury. PLoS ONE 2008; 3: e1861.
59. Ruan Q, Johnson GV. Transglutaminase 2 in neurodegenerative disorders. Front Biosci 2007; 12: 891-904.
60. Shweke N, Boulos N, Jouanneau C et al. Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. Am J Pathol 2008; 173: 631-42.
61. Shao M, Cao L, Shen C et al. Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res 2009; 69: 9192-201.
62. Xia J, Bergseng E, Fleckenstein B et al. Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in coeliac disease. Bioorg Med Chem 2007; 15: 6565-73.
63. Kapoerchan VV, Wiesner M, Overhand M, van der Marel GA, Koning F, Overkleeft HS. Design of azidoproline containing gluten peptides to suppress CD4+ T-cell responses associated with coeliac disease. Bioorg Med Chem 2008; 16: 2053-62.
64. Kapoerchan VV, Wiesner M, Hillaert U et al. Design, synthesis and evaluation of high-affinity binders for the coeliac disease associated HLA-DQ2 molecule. Mol Immunol 2010; 47: 1091-7.
65. Jüse U, van de Wal Y, Koning F, Sollid LM, Fleckenstein B. Design of new high-affinity peptide ligands for human leukocyte antigen-DQ2 using a positional scanning peptide library. Hum Immunol 2010; 71: 475-81.
66. Larche M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005; 11: S69-76.
67. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002; 360: 47-53.
68. Verhoef A, Alexander C, Kay AB, Larche M. T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med 2005; 2: e78.
69. Arentz-Hansen H, Körner R, Molberg Ø et al. The intestinal T cell response to α-gliadin in adult coeliac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med 2000; 191: 603-12.
70. Tye-Din JA, Stewart JA, Dromey JA et al. Comprehensive, quantitative mapping of T cell epitopes in gluten in coeliac disease. Sci Transl Med 2010; 2: 41ra51.
71. Tollefsen S, Arentz-Hansen H, Fleckenstein B et al. HLA-DQ2 and -DQ8 signatures of gluten T cell epitopes in coeliac disease. J Clin Invest 2006; 116: 2226-36.
72. o DQ8 transgenic mice. J Immunol 2009; 183: 2390-6.
73. Beaurepaire C, Smyth D, McKay DM. Interferon-gamma regulation of intestinal epithelial permeability. J Interferon Cytokine Res 2009; 29: 133-44.
74. Utech M, Ivanov AI, Samarin SN et al. Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane. Mol Biol Cell 2005; 16: 5040-52.
75. Gonzalez-Mariscal L, Lechuga S, Garay E. Role of tight junctions in cell proliferation and cancer. Prog Histochem Cytochem 2007; 42: 1-57.
76. McKerracher L, Higuchi H. Targeting Rho to stimulate repair after spinal cord injury. J Neurotrauma 2006; 23: 309-17.
77. LoGrasso PV, Feng Y. Rho kinase (ROCK) inhibitors and their application to inflammatory disorders. Curr Top Med Chem 2009; 9: 704-23.
78. Reinisch W, de Villiers W, Bene L et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010; 16: 233-42.
79. Herold KC, Gitelman S, Greenbaum C et al. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5years. Clin Immunol 2009; 132: 166-73.
80. Wiczling P, Rosenzweig M, Vaickus L, Jusko WJ. Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus. J Clin Pharmacol 2010; 50: 494-506.
81. Sandborn WJ, Colombel JF, Frankel M et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut 2010; 59: 1485-92.
82. Chatenoud L. Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nat Rev Endocrinol 2010; 6: 149-57.
83. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
84. Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-88.
85. Pescovitz MD, Bloom R, Pirsch J, Johnson J, Gelone S, Villano SA. A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. Am J Transplant 2009; 9: 2324-30.
86. Sollid LM, Molberg Ø, McAdam S, Lundin KE. Autoantibodies in coeliac disease: tissue transglutaminase - guilt by association? Gut 1997; 41: 851-2.
87. Mei HE, Frolich D, Giesecke C et al. Steady state generation of mucosal IgA+ plasmablasts is not abrogated by B cell depletion therapy with rituximab. Blood 2010; 116: 5181-90.
88. Yokoyama S, Watanabe N, Sato N et al. Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. Proc Natl Acad Sci USA 2009; 106: 15849-54.
89. Walters MJ, Wang Y, Lai N et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2010; 335: 61-9.
90. Anderson RP, van Heel DA, Tye-Din JA et al. T cells in peripheral blood after gluten challenge in coeliac disease. Gut 2005; 54: 1217-23.
91. Ráki M, Fallang LE, Brottveit M et al. Tetramer visualization of gut-homing gluten-specific T cells in the peripheral blood of coeliac disease patients. Proc Natl Acad Sci USA 2007; 104: 2831-6.